Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Mercola is an experienced and innovative translational scientist. In addition to directing Translational Cancer Biology at UC Irvine since 2005, he is PI of the UC Irvine Strategic Partners for the Evaluation of Signatures of Cancer (SPECS) consortium, which liaises with seven external institutes for the development of prognostic biomarkers using genomic methods. Results of these studies have been used for patent filing by UC Irvine and have been exclusively licensed to Proveri Inc., a company cofounded by Dr. Mercola to develop the translation of SPECS IP. Dr. Mercola was also a co-developer of chromatin immunoprecipitation for the analysis of cancer cells. He was selected as ÂSan Diego Padres Medical All-StarÂ for 2004.
chromatin immunoprecipitation for the analysis of cancer cells